Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 1;33(2):175-181.
doi: 10.53854/liim-3302-3. eCollection 2025.

Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii

Irene Terzi  1 , Periklis Panagopoulos  2 , Petros Rafailidis  2
Affiliations
Review

Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii

Irene Terzi et al. Infez Med. .

Abstract

Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a critical global health threat, particularly among hospitalized and critically ill patients, due to its association with severe, difficult-to-treat infections. Its high resistance stems from genomic plasticity, biofilm formation, and environmental persistence, leading to limited treatment options and high mortality. Existing treatments often rely on sulbactam-based combinations, yet resistance continues to rise and new agents remain limited.

Aims: This review aims to highlight the therapeutic potential of zosurabalpin, a first-in-class lipopolysaccharide (LPS) transport inhibitor with selective activity against A. baumannii, by summarizing preclinical and early clinical data on its efficacy, mechanism of action, pharmacokinetics, and safety.

Sources: Peer-reviewed publications from PubMed and Scopus, clinical data from ClinicalTrials.gov, and relevant conference materials ECCMID and IDWeek.

Content: Zosurabalpin inhibits the LptB-FGC complex, blocking LPS transport and causing lethal intracellular accumulation. Preclinical data demonstrate potent in vitro and in vivo activity against CRAB, with high selectivity and favorable pharmacokinetics. Phase 1 studies report good tolerability and a promising safety profile.Its novel mechanism makes zosurabalpin a strong candidate for treating CRAB.

Implications: With rising resistance and limited effective treatments, zosurabalpin offers a new, targeted therapeutic approach. Continued clinical development could help close a critical gap in the management of multidrug-resistant Acinetobacter baumannii.

Keywords: Carbapenem-resistant Acinetobacter baumannii (CRAB); LPS transport inhibitors; lipopolysaccharide (LPS) transport system; zosurabalpin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Mechanism of action of zosurabalpin through inhibition of the LptB2FGC transporter complex in Acinetobacter baumannii (based on concepts and structures described in references [18], [21], [–24]).
See this image and copyright information in PMC

References

    1. O’Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: how viable are the current options? Pharmacotherapy. 2021;41(9):762–780. - PubMed
    1. Butler DA, Biagi M, Tan X, et al. Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21(12):46. - PubMed
    1. Shan W, Kan J, Cai X, et al. Insights into mucoid Acinetobacter baumannii: a review of microbiological characteristics, virulence, and pathogenic mechanisms in a threatening nosocomial pathogen. Microbiol Res. 2022;261:127057. - PubMed
    1. Cruz-López F, Martínez-Meléndez A, Villareal-Treviño L, et al. Contamination of healthcare environment by carbapenem-resistant Acinetobacter baumannii. Am J Med Sc. 2022;364(6):685–694. - PubMed
    1. Karampatakis T, Tsergouli K, Behzadi P. Pan-genome plasticity and virulence factors: a natural treasure trove for Acinetobacter baumannii. Antibiotics (Basel) 2024;13(3):257. - PMC - PubMed

LinkOut - more resources